Τόμος 23 (2005) – Τεύχος 3 – Άρθρο 3 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 23 (2005) – Issue 3 – Article 3 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Βασίλης Α. Κόκκας, Παύλος Κ. Παπαδόπουλος, Κωνσταντίνος Λ. Παπαδόπουλος

Εργαστήριο Φαρμακολογίας και Β΄ Καρδιολογική Κλινική, Τμήμα Ιατρικής, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς

B.A. Kokkas, P.L. Papadopoulos, C.L. Papadopoulos

Departments of Pharmacology and 2^nd Cardiol­ogy, Medical School of the Aristotle University, Thessaloniki, Greece

2. National Heart, Lung and Blood Institute of Circulatory and Respiratory Health: Inflammation and thrombosis. http:/www.nhlbi.nich.gov/ (2003)

3. Adamson J., Longo D.: Hematologic alterations. In: (Braunwald E. et al., eds) Harrison’s. Principles of Internal Medicine. Pp. 348-360, McGraw-Hill, New York, 2001

4. Pinckard R.: Pathophysiology of the inflammatory Proc­ess. Inflammation Lectures-1998, Internet-Medline, 2003

5. Morrow J., Roberts L.J.: Lipid derived autocoids. In: (Hardman J., Limbird L. eds). Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. Pp 669-685, McGraw-Hill, New York, 1999

6. Holger U., Einar E., Lennart L.: Leucocyte and endothe­lial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol. Sci. 24: 640-646 (2003)

7. Williams M., Bray P.: Genetics of arterial prothrombotic risk states. Exp. Biol. Med. 226: 409-419 (2001)

8. Marnett L. and Kalgutkar A.: Cyclooxygenase 2 inhibi­tors. Discovery selectivity and the future. Trends Pharma-col. Sci. 20: 465-469 (1999)

9. Ahluwalia A., Perretti M.: B₁ receptors as new inflam­matory target. Could this B the 1? Trends Pharmacol. Sci. 20: 100-104 (1999)

10. Smith W., Garavito M., DeWitt D.: Prostaglandin endoperoxide H synthases (cyclooxygenases-1 and 2. J. Biol. Chem. 271: 33157-33160 (1996)

11. Guyton A., Hall J.: Textbook of Medical Physiology. Saunders W. Company. Philadelphia USA, 1996

12. Loll P., Picot D., Garavito R.: The structural basis of aspirin activity inferred from crystal structure of inactivated prostaglandin H₂ synthase. Nat. Struct. Biol. 2: 637-643 (1995)

13. Morrow J., Roberts J.K.: Lipid-derived autocoids. In: (Hardman J., Limbird L., eds) Goodman and Gilmans. The Pharmacological Basis of Therapeutics. Pp. 669-685, McGraw-Hill, New York, 2001

14. Roberts D., Cashel J., Guo N.: Purification of throm­bospondin from human platelets. J. Tissue Culture Meth­ods 16: 217-222 (1994)

15. Vallejo A., Mugge L., Khmink P.: Central role of throm­bospondin-1 in the activation and clone expansion of in­flammatory T-cells. J. Immunol. 164: 2942-2954 (2000)

16. Roberts D.: Regulation of tumor growth factor and metastasis by thrombospondin-1. Faser J. 10: 1183-1191 (1996)

17. Chandrasekaram L., He C., Al Bazai H.: Cell contact-dependent activation of α3β1 integrin modulates endothe­lial cell responses to thrombospondin-1. Mol. Cell Biol. 11: 2885-2900 (2000)

18. Dawson D., Pearce S., Zhong R.: CD36 mediates in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138: 707-717 (1997)

19. Lange-Asschenfeldt B., Weninger W., Velasko P.: Increased and prolonged inflammation and angioigenesis in delayed-type hypersensitivity reactions elecited in skin of thrombospondin-2 deficient mice. Blood 99: 538-545 (2002)

20. Chen D., Asahara T., Krasinski K.: Antibody blockade of thrombospondin accelerates reendothelialization and reduces neointima formation in balloon injected rat carotid artery. Circulation 100: 849-854 (1999)

21. Goldblum S., Young B., Wang P.: Thrombospondin-1 induces tyrosine kinase phosphorylation of adherens func­tion and regulates an endothelial paracellular pathway. Cell Biology 10: 1537-1551 (1999)

22. Retzinger G., DeAnglis A., Einhans C.: Fibrin(ogen) and inflammation. In: Wellcome to the laboratory of G. Retzinger MD, PhD. Inernet-medline, 2000

23. Cocks T., Moffatt J.: Protease-activated receptors. Sentries for inflammation? Trends Pharmacol. Sci. 21: 103-108 (2000)

24. Vergnolle N., Wallace J., Bunnett N., Hollenberg M.: Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol. Sci. 22: 146-152 (2001)

25. Murray R., Granner D., Mayes P., Rodwell V. (eds): Harper’s Biochemistry. Prentice-Hall, London 1990

26. Huntington J., Beglin T.: Targeting thrombin-rational drug design from natural mechanisms. Trends Pharmacol. Sci. 24: 589-596 (2003)

27. Fiorucci St., Distruti E.: Role of PAR2 in pain and in­flammation. Trends Pharmacol.Sci. 23: 153-155 (2003)

28. Cirino G., Napoli C., Bucci M., Cicale C.: Inflammation-coagulation network. Are serine protease receptors the knot? Trends Pharmacol. Sci. 21: 170-173 (2000)

29. Smith A.: Pass the protease: new ineractions between GPCRs. Trends Pharmacol. Sci. 21: 291 (2000)

30. Torra I.P., Genois P.H., Staels B.: Peroxisome prolif­erator-activated receptor alpha in metabolic disease, in­flammation, atherosclerosis and aging. Curr. Opin. Lipidol. 10: 151-159 (1999)

31. Gervois P., Torra I., Fruchart J., Staels B.: Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin. Chem. Lab. Med. 38: 3-11 (2000)

32. Κόκκας B., Κ.Λ. Παπαδόπουλος, Π.Κ.Παπαδόπουλος: PPAR–υποδοχείς και αντιαθηρωσκληρωτικοί μηχανισμοί. Επιθ. Κλιν. Φαρμακολ. Φαρμακοκιν. 18: 11-17 (2000)

33. Spiegelman B.: PPAR-gamma; adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514 (1998)

34. Gotto A., Pownall H. (eds): Manual of Lipid Disorders. Lippincott Williams and Wilkins, Philadelphia, 2003

35. Winegar D., Su J., Kliewer St.: Role of peroxisome proliferator-activated receptors in atherosclerosis. Current Opinion Cardiov. Pulm. Renal Investig. Drugs 2: 233-243 (2000)

36. Ye P., Hu X., Zhao Y.: PPARs activators in human endothelial cells increases plasminogen activator inhibitor type-1 expression. In: Abstract Book of the first intern. Symposium on PPARs. Fondazione G. Lorenzini, Milan, p. 39, 2001

37. Barter P.H.: Anti-inflammatory properties of high den­sity lipoproteins. In: Abstract Book of the first Intern. Sym­posium on PPARs. Fondazione G. Lorenzini, Milan, p. 13, 2001

38. Grip O., Lindgren S., Janciauskiene S.: Atorvastatin induces PPAR gamma and attenuate inflammatory re­sponse in human monocytes. In: Abstract Book of the first Intern. Symposium on PPARs. Fondazione G. Lorenzini, Milan, p. 33, 2001

39. Six I., Jaboureck O., Bouly M.: PPAR-alpha activator fenofibrate restores endothelial function and decreases cyclooxygenase-1 media expression in spontaneously hypertensives. In: Abstract Book of the first Intern. Sympo­sium on PPARs. Fondazione G. Lorenzini, Milan, p. 40, 2001